↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Bujanover S.) "

Search: WFRF:(Bujanover S.)

Result 1-3 of 3

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Escher, JC, et al. (author) Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria 2005 In: Journal of pediatric gastroenterology and nutrition. - : Ovid Technologies (Wolters Kluwer Health). - 0277-2116. ; 41:1, s. 1-7 Journal article (peer-reviewed)
2.	Malhotra, A., et al. (author) Effects of solriamfetol treatment on body weight in participants with obstructive sleep apnea or narcolepsy 2022 In: Sleep Medicine. - : Elsevier BV. - 1389-9457. ; 100, s. 165-173 Journal article (peer-reviewed)abstract Objectives: This analysis characterized changes in weight in participants with obstructive sleep apnea (OSA) or narcolepsy treated with solriamfetol (SunosiTM) 37.5 (OSA only), 75, 150, or 300 mg/d. Methods: In two 12-week, randomized, placebo-controlled trials and one 1-year open-label extension study, changes in weight were evaluated from baseline to end of study (week 12 or week 40 of the open -label extension [after up to 52 weeks of solriamfetol treatment]) in participants with OSA or narcolepsy. Results: After 12 weeks of solriamfetol treatment, median percent change in weight from baseline across all solriamfetol doses was-0.84%, compared with 0.54% for placebo, in participants with OSA; and-0.07%, compared with 3.08% for placebo, in participants with narcolepsy. After up to 52 weeks of solriamfetol treatment, overall median percent change in weight from baseline was-1.76%, which showed a dose-dependent pattern (75 mg, 0.57%; 150 mg,-1.2%; 300 mg,-2.5%).Results were similar in subgroups of participants with OSA or narcolepsy, with overall median percent changes in weight of-2.2% and-1.1%, respectively. After up to 52 weeks of solriamfetol treatment, the percentage of participants with weight loss >= 5% relative to baseline was 25.7% overall and increased in a dose -dependent manner (75 mg, 4.5%; 150 mg, 17.3%; 300 mg, 32.4%). Results were similar among sub-groups of participants with OSA or narcolepsy, with 26.4% and 24.2% of participants experiencing weight loss >= 5%, respectively. No weight-related treatment-emergent adverse events were serious.Conclusions: Solriamfetol treatment was associated with decreases in body weight in a dose-related manner.(c) 2022 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
3.	Edwards, RR, et al. (author) Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations 2016 In: Pain. - : Ovid Technologies (Wolters Kluwer Health). - 1872-6623 .- 0304-3959. ; 157:9, s. 1851-1871 Journal article (peer-reviewed)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-3 of 3

Refine your search

Type of publication: journal article (3)

Type of content: peer-reviewed (3)

Author/Editor: Bujanover, S (2); Hansson, P. (1); Tobias, J. (1); Chen, D (1); Baron, R (1); Wen, W (1); show more...; Kolacek, S (1); Malhotra, A (1); Hedner, Jan A, 1953 (1); Montgomery, SM (1); Hugot, JP (1); Levine, A (1); Rice, ASC (1); Dworkin, RH (1); Gewandter, JS (1); Turk, DC (1); Koletzko, S (1); Freeman, R (1); Attal, N (1); Redline, S. (1); Edwards, RR (1); Yarnitsky, D (1); Pepin, J. L. (1); Paerregaard, A (1); Jenkins, H (1); Scholz, J (1); Carr, D. (1); Dias, JA (1); Murch, SH (1); Smith, SM (1); Escher, JC (1); Hildebrand, H (1); Arendt-Nielsen, L (1); Katz, NP (1); Burke, LB (1); Cowan, P (1); Rappaport, BA (1); Cucchiara, S (1); Porter, L (1); Buderus, S (1); Sandhu, BK (1); Fell, JME (1); Angst, MS (1); Dionne, R (1); Haroutounian, S (1); Brell, J (1); Chappell, AS (1); Etropolski, M (1); Fillingim, RB (1); Kopecky, EA (1); show less...

University: Karolinska Institutet (2); University of Gothenburg (1)

Language: English (3)

Research subject (UKÄ/SCB): Medical and Health Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view